

# 1 Increased PCR screening capacity using a multi-replicate pooling scheme

2 A. Viehweger<sup>1,4</sup> \* (c), F. Kühnl<sup>2</sup> \*, C. Brandt<sup>3,4</sup>, B. König<sup>1</sup>, A. C. Rodloff<sup>1</sup>

3 \* These authors contributed equally.

4 <sup>1</sup> Institute for Medical Microbiology and Epidemiology of Infectious Diseases, University Hospital Leipzig

5 <sup>2</sup> Interdisciplinary Center of Bioinformatics, University Leipzig

6 <sup>3</sup> Institute for Infectious Diseases and Infection Control, Jena University Hospital

7 <sup>4</sup> nanozoo GmbH, Leipzig

8 (c) Corresponding author: [adrian.viehweger@medizin.uni-leipzig.de](mailto:adrian.viehweger@medizin.uni-leipzig.de)

## 9 **Abstract**

10 Effective public health response to viral outbreaks such as SARS-CoV-2 require reliable information about  
11 the spread of the infecting agent. Often real-time PCR screening of large populations is a feasible method  
12 to generate this information. Since test capacities are usually limited, pooling of test specimens is often  
13 necessary to increase screening capacity, provided that the test sensitivity is not significantly compromised.  
14 However, when a traditional pool is tested positive, all samples in the pool need individual retesting, which  
15 becomes ineffective at a higher proportion of positive samples. Here, we report a new pooling protocol  
16 that mitigates this problem by replicating samples across multiple pools. The resulting pool set allows the  
17 sample status to be resolved more often than with traditional pooling. At 2% prevalence and 20 samples  
18 per pool, our protocol increases screening capacity by factors of 5 and 2 compared to individual testing  
19 and traditional pooling, respectively. The corresponding software to layout and resolve samples is freely  
20 available under a BSD license (<https://github.com/phiweger/clonpool>).

## 21 Main text

22 Pooling of test specimen has long been used to screen larger collections of samples, when most of them  
23 are expected to test negative.<sup>1</sup> In outbreak situations such as the current SARS-CoV-2 pandemic, this  
24 “pooling” allows screening of large populations to guide public health response. However, in most labora-  
25 tories, the screening capacity is limited by the number of PCR reactions that can be performed in a given  
26 time. It is, therefore, desirable to maximize the number of samples that can be tested per reaction.

27 Various approaches have been proposed to do so in the context of SARS-CoV-2 RT-PCR testing.<sup>2,3</sup> One  
28 problem with the traditional pooling approach, where several samples are collected and tested collectively,  
29 is that the number of positive pools that require individual retesting increases rapidly with the number  
30 of positive samples in the overall population. A high prevalence of the target renders traditional pooling  
31 ineffective. To mitigate this, we propose to test specimens in replicates and distribute them across multiple  
32 pools. The resulting “pool address” can then be used to resolve samples in one pool, given the information  
33 from other pools that contain a replicate. While some previous studies have taken a similar approach  
34 implicitly,<sup>2</sup> it has neither been investigated systematically for more replicates than two, nor is there any  
35 software that would generate and resolve the corresponding pooling layout for laboratory use.

36 We therefore introduce “clonepool”, a pooling framework to maximize the effective number of samples  $s_e$   
37 per PCR reaction. “Effective” refers to the fact that samples in positive pools, whose status cannot be  
38 resolved in the pooled run, are assumed to be retested individually. The maximum number of samples for  
39 a given pool size  $p$ , number of pools  $n$  and number of replicates  $r$  is calculated as  $s_m = \frac{pn}{r}$ . The effective  
40 number of samples can then be calculated from the number of unresolved samples  $s$  as  $s_e = \frac{s_m}{p+s}$ .

41 The clonepool algorithm first distributes all sample replicates randomly across the available pools, with  
42 the limitation that a sample’s replicates do not co-occur in the same pool. After the pools have been  
43 tested, the algorithm attempts to resolve the samples’ status in two phases: In a first phase, all samples  
44 that have at least one replicate in a negative pool are marked negative. In the second phase, samples that  
45 (a) only occur in positive pools, and (b) have at least one replicate in a pool in which all other samples  
46 are known to be negative, are marked positive (red, orange). All other samples cannot be resolved, and  
47 need to be retested individually. The longer the set of pools a sample is distributed across, i.e., the larger  
48 its pool set, the more samples can be resolved given a particular prevalence. Of course, a higher number  
49 of replicates comes at the price of a reduced number of samples which can be processed at a fixed number

50 of wells. Fortunately, our results provide an efficient means to find the optimal trade-off for any given set  
51 of parameters.




Figure 1: Illustration of the clonepool algorithm. Circles denote the wells, each containing a pool of samples (small squares). A distinct color marks all replicates of a single sample. Positive samples are flagged with “+”, negative ones remain empty. Positive pools are shaded in grey, negative ones in white. In a first phase, all samples that have at least one replicate in a negative pool are identified as negative (blue, green). In the second phase, samples that only occur in positive pools and where at least one replicate is in a pool where all other samples are negative, are recognized as positive (red, orange). All other samples cannot be resolved and have to be retested individually (yellow).

52 We tested the proposed clonepool algorithm using simulated data. We assumed no pipetting errors,  
53 which can be achieved, e.g., through the use of a pipetting robot. We also assume that 94 pools are  
54 available, which corresponds to a 96-well plate with two wells reserved for a positive and a negative  
55 control. Furthermore, we assume that there are no false positive or false negative PCR reactions.

56 Two parameters determine which pooling scheme is most effective (Fig. 2). If both the prevalence and  
57 the number of samples per pool are low, traditional pooling without replicates yields the highest number  
58 of samples per reaction. However, as the prevalence increases or more and more samples are pooled,  
59 the number of positive pools increases, causing a large number of retested samples and thus reducing the  
60 overall throughput. Using sample replicates will then allow to resolve more samples than in the traditional  
61 approach. In our testing experience, we observed a prevalence of about 5%, but this value is subject to  
62 variability, e.g., depending on a population’s pre-test probability.

63 The number of samples that can be pooled without affecting the PCR sensitivity is limited by the PCR  
64 cycle threshold (Ct) for the target, i.e., the cycle at which amplification becomes detectable over back-  
65 ground noise (typically ten times the standard deviation, SD). Usually, Ct values above 35 are treated  
66 as unspecific amplification. SARS-CoV-2 amplifies at low Ct values due to high viral titers (Ct 18-25  
67 depending on the material and number of days post-infection).<sup>4,5</sup> A 20-fold dilution, i.e., pooling 20 sam-  
68 ples, would cause the Ct value to increase by about 4.3 cycles ( $2^x = d$ , where d is the dilution and x the

69 shift in Ct), which still lies comfortably above the detection limit.




Figure 2: Simulation results for different percentages of positive samples (x-axis), replicates (colors), and pool sizes (panels). The target metric is the effective number of samples per PCR reaction, which includes the individual retesting of samples that cannot be resolved in the first pooling run.

70 At a prevalence of 5% SARS-CoV-2 positive samples, and for ten samples per pool and two replicates per  
71 sample, we simulate that 2.61 times the number of samples can be processed compared to testing samples  
72 individually (SD 0.13). This result is in line with previous estimates using a slightly different version of  
73 the 2-replicate scheme.<sup>2</sup> Using two replicates increases the effective number of samples per reaction by  
74 31% compared to pooling without replicates. At 2% prevalence and 20 samples per pool – a scenario  
75 more akin to screening large populations – 5.01 times the number of samples can be screened compared  
76 to individual testing (SD 0.28), and the increase over traditional pooling is 193%. These presented values  
77 correspond to *in silico* simulations, and require further validation in the laboratory.

78 In conclusion, our pooling protocol based on sample replicates can substantially increase the number of  
79 samples per PCR reaction when screening large populations during pathogen outbreaks, such as SARS-

80 CoV-2. The protocol can be tuned to local laboratory conditions such as pool size and proportion of  
81 positive samples. Also, subsequent testing of positive pools could be made more efficient by splitting  
82 pools iteratively.<sup>6</sup>

83 The clonpool software supports the protocol's implementation for routine use ([https://github.com/](https://github.com/phiweger/clonpool)  
84 [phiweger/clonpool](https://github.com/phiweger/clonpool)).

85 **References**

- 86 1. Dorfman, R. The detection of defective members of large populations. *Ann. Math. Stat.* **14**, 436–440  
87 (1943).
- 88 2. Sinnott-Armstrong, N., Klein, D. & Hickey, B. Evaluation of group testing for SARS-CoV-2 RNA.  
89 *medRxiv* (2020).
- 90 3. Eis-Huebinger, A. M. *et al.* Ad hoc laboratory-based surveillance of SARS-CoV-2 by real-time RT-PCR  
91 using minipools of RNA prepared from routine respiratory samples. *medRxiv* (2020).
- 92 4. Wölfel, R. *et al.* Virological assessment of hospitalized patients with COVID-2019. *Nature* (2020).
- 93 5. Holshue, M. L. *et al.* First case of 2019 novel coronavirus in the united states. *N. Engl. J. Med.* **382**,  
94 929–936 (2020).
- 95 6. Eberhardt, J. N., Breuckmann, N. P. & Eberhardt, C. S. Multi-Stage group testing optimizes COVID-  
96 19 mass population testing. *medRxiv* (2020).